Introduction/Background Previous studies have found pretreatment thrombocytosis and elevated C-reactive protein (CRP) to be associated with worse prognosis in endometrial cancer. The aim of this study was to appraise these conditions and their relationship with survival outcome for women diagnosed with endometrial cancer treated at a tertiary center.

Methodology This retrospective study evaluated 324 patients who underwent staging surgery for endometrial cancer and standard of care adjuvant therapy as indicated. We utilized Kaplan Meier and Cox regression analysis to assess the five-year survival rate (5-YSR) with respect to platelet counts and CRP levels.

Results The median age was 64 (IQR: 57, 70) and the average BMI was 32.2 (IQR: 25.8, 36.6) in our cohort. Univariate analysis showed a worse 5-YSR for both high and low platelet counts (≥ 400 x E9/L, HR = 4.32, 95% CI [1.67, 11.17], p = 0.003; ≤ 149 x E9/L, HR = 3.81, 95% CI [1.34, 10.86], p = 0.01) as well as for elevated CRP (≥ 10 mg/L, HR = 3.59, 95% CI [1.81, 7.10], p = 0.0002). However, multivariate modeling incorporating stage, histology and grade indicated that, of the two biomarkers in question, only elevated CRP had a significant effect on the 5-YSR (HR = 2.51, 95% CI [1.20, 5.23], p = 0.01).

• Download figure
• Open in new tab
• Download powerpoint

Abstract #775 Figure 1

Kaplan-Meier plots below demonstrate abnormal platelet counts (≥400 E9/L or ≤=149 E9/L) and elevated CRP levels (≥10 mg/L) are associated with a worse five-year survival rate.

Conclusion Assessment of CRP levels and platelet counts prior to treatment may be a simple and accessible way to improve risk stratification and guide management of endometrial cancer. Elevated CRP may serve as an independent indicator of poor prognosis.

Disclosures N/A